United States Mold Inhibitors Market Size & Outlook, 2026-2034
United States Mold Inhibitors Market Insights
- According to Reed Intelligence analysis, the United States Mold Inhibitors Market size was USD 320.58 Million in 2025 and is projected to reach USD 498.17 Million by 2034.
- The United States market is projected to grow at a CAGR of 5.02% between 2026 and 2034.
- By segment, Natural mold inhibitors emerged as the largest By Type in terms of market size in 2025.
- Natural mold inhibitors is anticipated to remain the most attractive By Type segment, recording the fastest growth during the forecast period.
![United States Mold Inhibitors Market Size, Share & Growth Report By [2034]](https://reedintelligence.com/uploads/charts/united-states-mold-inhibitors-market-united-states-by-type-247860.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, United States represented 23.92% of the overall global Mold Inhibitors Market size.
- United States is projected to lead the global Mold Inhibitors Market size by 2034.
- Across North America, United States is anticipated to hold the dominant position in market size by 2034.
- Canada is forecasted to expand at the fastest pace in North America, attaining USD 145.15 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 320.58 Million |
| Market Size In 2034 | USD 498.17 Million |
| Largest segment | Natural mold inhibitors |
| Units | Revenue in USD Million |
| CAGR | 5.02% (2026-2034) |
| Segmnetation Covered | |
| By Type |
|
| By Source |
|
| By Application |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United States Mold Inhibitors Market By Type 2026-2034 (USD Million)
| By Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Natural mold inhibitors | XX.x | XX.x | XX.x | 205.68 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Synthetic mold inhibitors | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United States Mold Inhibitors Market By Source 2026-2034 (USD Million)
| By Source | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plant | XX.x | XX.x | XX.x | 132.75 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Animal | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Micro-Organism | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United States Mold Inhibitors Market By Application 2026-2034 (USD Million)
| By Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foods & Beverages | XX.x | XX.x | XX.x | 137.11 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Animal Feed | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pharmaceuticals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Cosmetics and Personal Care | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.